The Mesoblast Ltd (ASX: MSB) share price could be in focus after the company secured US FDA approval for a new potency assay for its commercially approved Ryoncil (remestemcel-L-rknd). This milestone further strengthens quality controls for its flagship cell therapy product.
What did Mesoblast report?
- Received FDA approval for the T-cell Proliferation Inhibition BioAssay (TIBA), a new potency assay for Ryoncil.
- TIBA will be used alongside existing assays to ensure consistent product quality.
- Ryoncil remains the only FDA-approved MSC therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older.
- The new assay supports ongoing manufacturing improvements and quality monitoring for commercial product lots.
What else do investors need to know?
Mesoblast’s updated testing process aims to improve the release and stability monitoring of each batch of Ryoncil. The TIBA assay offers added sensitivity to detect any changes in potency during manufacturing scale-up or when production shifts to new facilities.
Mesoblast continues to develop and expand its cell therapy portfolio, with Ryoncil being evaluated for additional diseases and rexlemestrocel-L in late-stage trials for heart failure and chronic lower back pain.
What’s next for Mesoblast?
The new assay’s FDA approval paves the way for smooth ongoing commercialisation of Ryoncil. Mesoblast remains focused on broadening Ryoncil’s use to other inflammatory conditions and advancing its other cell therapies.
Investors can look for updates as the company works toward new product indications, international partnerships, and continued investment in manufacturing and intellectual property.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have declined 8%, trailing the S&P/ASX 200 Index (ASX: XJO), which is flat over the same period.
The post Mesoblast wins FDA nod for new Ryoncil potency test appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mesoblast right now?
Before you buy Mesoblast shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 2 ASX 200 shares tipped by brokers to return 73% and 83%
- Brokers rate these 5 ASX shares as a strong buy, and tip upsides of 28% to 62%
- 7 ASX healthcare stock picks from Bell Potter
- Here are the top 10 ASX 200 shares today
- 3 ASX healthcare shares to buy with 25% to 100% upside as sector rebound races higher
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.